NCT02950155View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis

PHASE3CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 16, 2016

Primary Completion Date

January 30, 2021

Study Completion Date

January 31, 2022

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

Rituximab

A single infusion at a dose of 500 mg Mabthera/Rituximab.

DRUG

Sodium Chloride solution

A single infusion of Placebo/Sham.

Trial Locations (1)

171 76

Karolinska University Hospital, Stockholm

All Listed Sponsors
lead

Fredrik Piehl

OTHER

NCT02950155 - A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis | Biotech Hunter | Biotech Hunter